INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a serious
progressive disorder characterized by insulin resistance and relative insulin deficiency resulting in increased blood glucose level. The prevalence of T2DM is growing worldwide, mainly due to growth in urbanization and the resulting substantial changes in lifestyle [1] . The total number of adults aged 20-79 with diabetes is projected to increase from 382 million in 2013 to 592 million in 2035 [1] . It has been estimated that 6.4% of adults aged 20-79 had diabetes in Sweden in 2013 [1] . T2DM is the most common form of diabetes worldwide, and is an established risk factor for several fatal and non-fatal microand macrovascular complications.
This translates into a significant economic burden for individuals and societies. In 2010, an estimated 8% of the total Swedish health expenditure went to diabetes-related healthcare [2] . Previous studies have shown that good glycemic control is crucial to decrease the risk Despite these guidelines and the availability of a range of drugs, a large proportion of T2DM patients fail to achieve and maintain the treatment goals, mainly due to the progressive nature of the disease and the inadequacy of conventional treatments [11] . A survey conducted in 2008 by the Swedish National Diabetes Register showed that while there was an improvement in the proportion of T2DM patients reaching HbA1c B 7% compared with 1999, a substantial proportion of patients (48%) still did not achieve this treatment goal [12] .
Similar values have been reported for years 2009-2012 [13] . In addition, conventional medications such as sulfonylurea or insulin are associated with side effects including weight gain and hypoglycemia [14, 15] . Hence, there is a need for new therapies with better efficacy and fewer side effects.
In response to this, incretin-based therapies have attracted growing interests during recent years, as clinical trials indicated that they might provide improved glycemic control with low risk of hypoglycemia and seem weight neutral, or even weight reducing [14, [16] [17] [18] . These therapies are mainly recommended as secondline therapy among patients who fail to achieve or maintain the blood glucose treatment goals on metformin alone [10] . 
METHODS
Model Description
The authors conducted this cost-utility analysis using the Swedish Institute for Health 
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Simulation Cohort, Treatment Effects and Scenarios
The baseline characteristics of the simulated cohort were based on a survey conducted by the Swedish National Diabetes Register [27] . As in this study, the authors evaluated the three second-line therapies as add-on to metformin, they used the data on a sample of patients on metformin monotherapy with HbA1c[7% consisting 30% of patients on metformin monotherapy in Ekstrom et al.'s study [27] ( Table 1 , data were provided by the Swedish National Diabetes Register).
Three treatment strategies evaluated in the study are presented in Fig. 1 [35, 36] . A recent meta-analysis found no direct association between dosage of insulin and risk of hypoglycemia [37] , and so the authors applied the same rate of hypoglycemia events for both insulin treatments in this study. To account for association between hypoglycemic events and changes in HbA1c, the reported event rate from a study is transferred to expected event rate using coefficient (1.43) from a previous study [38] .
As in previous studies, no treatment effect on other biomarkers was assumed in the base case analysis [39] [40] [41] [42] . This assumption was relaxed in the sensitivity analysis. When data on treatment effects of NPH insulin were not available, the authors used the results from glargine insulin, since previous studies reported no significant difference in treatment effects between NPH and glargine insulin [43] [44] [45] . Treatment effects were applied for the first year after treatment, and then a constant annual drift was assumed for different treatment strategies. An annual drift of 0.15% unit for HbA1c was assumed for all treatments [46] . The annual drifts in weight were 0.42 kg for insulin and 0.23 kg for other treatments in the base case analysis [47] . In the sensitivity analyses, the authors considered 0.23 kg and 0.1 kg change in weight for all treatments [48] . They assumed 0.3 mmHg and 0.03 mg/dl annual drifts in blood pressure and lipid levels, 
Costs and Utilities
In the base case, costs were accounted from a For the current study, these costs were extracted from a previous study in Sweden [54] inflated to year 2012 using consumer price index (see supplement for more details).
Baseline utility was modeled using data from a recent study on EQ-5D scores in Swedish T2DM patients with no complications [55] . Health state utilities for T2DM-related complications and utility decrements associated with age, gender, duration of diabetes, and BMI were derived, whenever possible, from Sweden-specific published sources, supplemented with data from other sources if necessary ( Table 2 in supplement). The same utility decrement was applied for subsequent events as for the initial one. No utility decrement associated with modality of treatment was applied in the base case analysis. Decrement associated with hypoglycemia was extracted from a previous study [56] which used data from the Swedish respondents in a multinational study [57] . A 3% annual discount rate for costs and qualityadjusted life years (QALYs) was applied in the base case analysis over a 35-year time horizon. While there is no formal willingness-to-pay (WTP) threshold for cost-effectiveness ratios in Sweden, interventions with less than 500,000 SEK per QALY gained are generally considered as cost-effective [58, 59] .
Sensitivity Analyses
The authors conducted a series of one-way sensitivity analyses to assess the impact of variation in the model inputs and assumptions on the results of the base case analysis. In a sensitivity analysis, they excluded the net consumption and productivity losses (applying healthcare payer perspective). The number of weekly SMBG performed by patients in the GLP-1 agonists ? metformin and DPP-4 inhibitors ? metformin groups was varied (3, 5, and 7), as were the time horizons (10 and 20 years) and the discount rate for costs and QALYs (0 and 5%). A utility decrement of 0.049 for insulin therapy was applied [60] . The annual drift in HbA1c was set to 0.10% and 0.20% unit, the cost of one SMBG was varied by 10% and 25%, and the cost of T2DM-related complications varied by ±20%. No major hypoglycemia and no moderate/major hypoglycemia were assumed for all treatment groups. The treatment effects on HbA1c were changed to the lower and upper limits of 95% CI of the main estimate [28] . In addition, the treatment effect on HbA1c for NPH insulin 60 IU/day was set to -0.56%, -0.35% [35] , and -0.18% [37] .
A probabilistic sensitivity analysis (PSA) was conducted to assess the joint uncertainty of the input parameters using a Monte Carlo simulation with 1,000 iterations. Nonparametric bootstrapping with 1,000 bootstrap samples was then used to calculate the mean and bootstrap bias-corrected (BBC) 95% confidence interval (CI) of costs and QALYs as well as incremental cost-effectiveness ratios (ICERs). In 
RESULTS
The simulated profiles of HbA1c change over time for three treatments as add-on to metformin are shown in Fig. 2 . It can be seen that using the base case threshold values, before switching to insulin therapy, patients on strategies 1 and 2 were expected to receive GLP-1 agonists and DPP-4 inhibitors, respectively, for 6 and 4 years. Figure 1 in the supplement displays the 35-year cumulative incidence of some major micro-and macrovascular events projected by the IHECM-T2DM. The model predicted a higher incidence of macrovascular events compared with 
Sensitivity Analysis
Overall, the univariate analyses showed that our base case analysis was robust to variation in the inputs and assumptions applied in the model. inhibitors, and this is in line with previous modeling studies comparing liraglutide with sitagliptin [20, [61] [62] [63] . The one-way sensitivity analyses in this study showed that this finding was most sensitive to the disutility due to BMI: assuming no disutility due to BMI [25 resulted in an ICER higher than SEK 500,000 per QALY gained. This is mainly due to significant difference between these two drug classes in weight changes (1.8 kg reduction versus no change) and implies that besides the effects on improved glycemic control, the effects on weight also play important role in costeffectiveness of treatments in the T2DM
context. In line with a previous study [62] , this finding suggests that there should be a subgroup of patients with BMI [25 where treatment strategy with GLP-1 agonists is even more cost-effective in comparison to DPP-4 inhibitors. In particular, a previous study in Sweden showed that BMI is a significant predictor of other biomarkers in T2DM
patients [64] . This implies that taking this association into account might decrease the ICER in favor of GLP-1 agonists, due to its effect on weight loss. The results were robust to other assumptions, and the ICER remained below SEK 500,000. The ICER reported in the current study is higher than in a previous study in Sweden [20] that used the same model to compare liraglutide versus sitagliptin. Differences in utility decrement, the baseline characteristics, and treatment effects might be potential explanations for different ICER values. The ICER is also higher than in previous studies in other countries [61] [62] [63] . Beside differences mentioned earlier, there are differences in perspective (societal versus healthcare payer), and applied model that limits comparability of this study with previous ones. All these studies applied the CORE diabetes model [65] , which mainly uses risk equations from the UKPDS Outcome Model-1 [24] for macro-and microvascular complications.
The authors used a different model (i.e., the IHECM-T2DM), which applies different risk equations including Swedish-specific macrovascular risk equations [21] [22] [23] 26 ].
In the comparison of incretin-based therapies against NPH insulin, while NPH insulin was associated with higher HbA1c reduction, it resulted in weight gain and a higher number of hypoglycemic episodes. The estimated ICER of both incretin-based secondline treatment strategies (1 and 2) remained below SEK 500,000. This finding is in line with a previous cost-utility analysis comparing the DPP-4 inhibitor saxagliptin against NPH insulin as add-on to metformin in Poland [39] .
In these treatment strategies, patients on incretin-based therapies benefit from an extra treatment compared with patients who initiate NPH insulin as second-line treatment, and this finding implies that the health benefits of providing second-line treatment prior to insulin introduction offset the higher prices of these medications.
However, it should be noted that the costeffectiveness of incretin-based therapies decreased as the HbA1c switching threshold value to NPH insulin increased. This implies that as the number of years on these treatments increases, the marginal costs of the treatments outweigh the marginal benefits, and the ICER rises. The similar finding was observed in a previous study in Sweden using the same model [20] . The one-way sensitivity analyses showed that the results were most sensitive to the assumptions related to incidence of hypoglycemia and disutility of hypoglycemia and insulin. However, this base case conclusion was robust against all these variations. The main strengths of the current study include: applying the baseline characteristics from a large sample of T2DM patients from routine practice in Sweden, using utility decrements for a number of complications from a Swedish sample with T2DM, applying Swedish-specific risk equations for macrovascular complications, and extracting treatment effects on the main biomarkers (i.e., 
